Stomach Cancer Clinical Trials
Stomach cancer clinical trials are important research studies that help physicians evaluate the effectiveness of new treatment approaches. Patients who are being treated for stomach cancer at Moffitt Cancer Center may be advised to consider opportunities to participate in suitable clinical trials during the course of their treatments. We encourage our patients to explore all of their options, which may include beneficial new therapies that are not yet available outside of clinical trial settings.
As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt is a well-respected leader in cancer research. Our stomach cancer clinical trials incorporate the collaborative expertise of our multispecialty team of medical professionals and provide us with a means to compare the effectiveness of current treatments with promising new options like:
- Immunotherapy drugs
- Combinations of conventional chemotherapies
- Novel molecularly targeted therapies
Additionally, the researchers and clinicians at Moffitt are investigating biomarkers that can help identify new stomach cancer treatments. We are also studying potential causes of resistance to new therapies.
It’s important to remember that all of today’s most widely recommended treatments for stomach cancer were once available only through research studies. If you are interested in exploring clinical trials, you do not need a referral to consult with the stomach cancer team at Moffitt. We can answer your questions and provide information about all of your treatment options, including both clinical trials and the current standard of care.
To learn more about the stomach cancer clinical trials available at Moffitt Cancer Center, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Our clinical trial navigators can help you find out if a trial is right for you, and no referrals are necessary.
Helpful Links:
-
Clinical Trials
CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:
CLINICAL TRIAL 21742
Remote Resistance Exercise Powering Survivors- Gastrointestinal Oncology (Remote REPS-:GI)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (); RMC-9805 ()
CLINICAL TRIAL 23230
Support through remote observation and nutrition guidance program for individuals with gastroesophageal cancer (STRONG-GEC)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23228
An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) with KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated with Imatinib (INSIGHT)
Condition: Sarcoma
Intervention: DCC-2618 (Ripretinib); Ripretinib (); Sunitinib ()
CLINICAL TRIAL 23257
Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-Cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: LB1908 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23480
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Condition: Multiple
Intervention: CGT4859 ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 23766
A First-in-Human Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of FID-022 as Monotherapy in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: FID-022 ()